DeepMed Research

UNIVERSITY OF ALABAMA AT BIRMINGHAM

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1969-01-01

Employees: 2K

Market Cap: -

Website: http://www.uab.edu

Clinical Trials

Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx

Phase 3

Terminated

Conditions: Head and Neck Cancer

Interventions: Procedure: conventional surgery
Biological: cetuximab
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2014-02-06

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 32

Registration Number: NCT00004227

Locations: 🇺🇸
Monmouth Medical Center, Long Branch, New Jersey, United States
🇺🇸
ImClone Systems, Incorporated, Somerville, New Jersey, United States
🇺🇸
Kimball Medical Center, Lakewood, New Jersey, United States

Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis

Phase 3

Completed

Conditions: Melanoma (Skin)

Interventions: Biological: recombinant interferon alfa
Procedure: lymphangiography
Drug: Observation

First Posted Date: 2003-01-27

Last Posted Date: 2014-01-20

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 3000

Registration Number: NCT00004196

Locations: 🇺🇸
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

and more 1 locations

Radiation Therapy Following Surgery in Treating Patients With Recurrent or Second Primary Cancer of the Head and Neck Following Previous Radiation Therapy

Phase 1

Conditions: Head and Neck Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-04

Lead Sponsor: University of Alabama at Birmingham

Registration Number: NCT00004226

Locations: 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸
Veterans Affairs Medical Center - Tampa (Haley), Tampa, Florida, United States

Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses

Phase 2

Withdrawn

Conditions: Precancerous Condition

Interventions: Drug: Placebo
Drug: celecoxib

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-05

Lead Sponsor: University of Alabama at Birmingham

Registration Number: NCT00027976

Locations: 🇺🇸
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States
🇺🇸
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
🇺🇸
Siteman Cancer Center at Barnes-Jewish Hospital, Saint Louis, Missouri, United States

and more 4 locations

AG2037 in Treating Patients With Advanced, Metastatic, or Recurrent Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-16

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 22

Registration Number: NCT00017524

Locations: 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 1

Terminated

Conditions: Lymphoma

Interventions: Biological: rituximab
Radiation: yttrium Y 90 ibritumomab tiuxetan

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-13

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 18

Registration Number: NCT00033423

Locations: 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
Stanford Comprehensive Cancer Center - Stanford, Stanford, California, United States
🇺🇸
Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham, Birmingham, Alabama, United States

Family Blood Pressure Program - HyperGEN

Completed

Conditions: Heart Diseases
Hypertension
Cardiovascular Diseases

First Posted Date: 2000-05-26

Last Posted Date: 2015-10-08

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 3604

Registration Number: NCT00005267

Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura

Phase 2

Completed

Conditions: Purpura, Thrombocytopenic, Idiopathic

First Posted Date: 2000-05-03

Last Posted Date: 2008-09-09

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 20

Registration Number: NCT00005652

Locations: 🇺🇸
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States

Phase I Study of Liposome-Mediated Gene Transfer in Patients With Cystic Fibrosis

Phase 1

Completed

Conditions: Cystic Fibrosis

First Posted Date: 2000-02-25

Last Posted Date: 2011-03-30

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 9

Registration Number: NCT00004806

Improving Vocational Outcomes in Arthritis

Phase 2

Completed

Conditions: Rheumatic Diseases
Musculoskeletal Diseases
Arthritis

Interventions: Behavioral: Standard of care
Behavioral: Vocational counseling intervention
Behavioral: Reading materials for control participants

First Posted Date: 1999-11-04

Last Posted Date: 2016-01-06

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 326

Registration Number: NCT00000407

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy